PELTHOS THERAPEUTICS INC (PTHS) Stock Price, Forecast & Analysis
NYSEARCA:PTHS • US1711262048
PTHS Key Statistics, Chart & Performance
The current stock price of PTHS is 24 USD. In the past month the price decreased by -5.22%.
PTHS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PTHS.
PTHS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTHS Forecast & Estimates
11 analysts have analysed PTHS and the average price target is 61.61 USD. This implies a price increase of 156.7% is expected in the next year compared to the current price of 24.
PTHS Ownership
PTHS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.62 | 403.74B | ||
| AMGN | AMGEN INC | 16.99 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.54 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.64 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.88 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.85 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.49 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.87 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTHS
Company Profile
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi (ozenoxacin) Cream, 1%, which is a non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Company Info
PELTHOS THERAPEUTICS INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA US
Employees: 4
Phone: 19199082422
PELTHOS THERAPEUTICS INC / PTHS FAQ
What does PELTHOS THERAPEUTICS INC do?
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi (ozenoxacin) Cream, 1%, which is a non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
What is the stock price of PELTHOS THERAPEUTICS INC today?
The current stock price of PTHS is 24 USD. The price increased by 3.27% in the last trading session.
Does PELTHOS THERAPEUTICS INC pay dividends?
PTHS does not pay a dividend.
What is the ChartMill rating of PELTHOS THERAPEUTICS INC stock?
PTHS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Is PELTHOS THERAPEUTICS INC (PTHS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PTHS.
Can you provide the number of employees for PELTHOS THERAPEUTICS INC?
PELTHOS THERAPEUTICS INC (PTHS) currently has 4 employees.
What is PELTHOS THERAPEUTICS INC worth?
PELTHOS THERAPEUTICS INC (PTHS) has a market capitalization of 74.16M USD. This makes PTHS a Micro Cap stock.